The Committee discussed the potential risk of gadolinium retention in the brain and other body organs in patients receiving gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) procedures. A majority of the Committee agreed with the plans that were proposed by the FDA to address this potential risk, which included labeling and potentially requiring further additional safety studies.
Back to All Events
Earlier Event: August 3Advisory Committee on Heritable Disorders in Newborns and Children
Later Event: September 11Pediatric Advisory Committee